The global breast reconstruction surgery and treatment market is forecasted to expand at 5.9% CAGR to reach a market valuation of US$ 1.61 Billion by the end of 2033, up from US$ 853.9 Million that was recorded for 2022.
The global breast reconstruction surgery and treatment market is anticipated to be driven by an increase in breast cancer prevalence, an increase in the number of breast reconstruction procedures, and a surge in demand for acellular dermal matrix.
| Attribute | Details |
|---|---|
| Breast Reconstruction Surgery and Treatment Market Size (2023) | US$ 901.3 Million |
| Forecasted Market Value (2033) | US$ 1.61 Billion |
| Value CAGR (2023 to 2033) | 5.9% |
| Collective Value Share: Top 5 Countries (2022) | 64.1% |
| Key Market Players | Mentor Worldwide LLC (Johnson & Johnson), Allergan Aesthetics (An AbbVie Company), Sientra, POLYTECH Health & Aesthetics GmbH, GC Aesthetics, Sebbim, Establishment Labs S.A., Integra Lifesciences, RTI Surgical Holdings, Idel Implant Incorporated, Laboratoires Arion, Silimed, Guangzhou Wanhe Plastic Material Co., Ltd., Cereplas, Hansbiomed, PMT Corporation, and PFM Medical |
Breast reconstruction, also referred to as breast augmentation, entails remodeling of the areola and nipple. Women typically undergo breast reconstruction. There are three types of breast reconstruction: autologous tissue reconstruction, implants/prosthetic reconstruction, and tissue and implant reconstruction.
Breast reconstruction with artificial implants is referred to as implants/prosthetic breast reconstruction. It is referred to as autologous tissue breast reconstruction when a portion of tissue from another region of the body is used to reconstruct the breast. Either autologous tissue reconstruction, implants/prosthetic reconstruction, or both types of reconstruction are used for breast augmentation.
Women who have undergone breast reconstruction deal with numerous issues.
Breast reconstruction using silicone and saline is frequently connected with problems. Breast reconstruction is typically done for cosmetic purposes or to restore breast volume that has been lost due to pregnancy, weight loss, or mastectomy for breast cancer. The best choice for breast reconstruction is breast reconstruction surgery.
When the entire breast or a portion of the breast is removed, breast reconstruction is performed.
They assist in coping with breast loss brought on by cancer and are also utilized for cosmetic purposes. During breast reconstruction surgery, the patient should have access to enough privacy.
According to Future Market Insights, the global market has huge growth potential due to the rising prevalence of breast cancer.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for breast reconstruction surgery and treatment expanded at a CAGR of 4.6% during the historic period (2017 to 2022) and reached a market value of US$ 853.9 Million in 2022.
The global market for breast reconstruction surgery and treatment accounts for around 1.5% of the global cosmetic surgery market valued at around US$ 55.6 Billion in 2022.
The global market for breast reconstruction surgery and treatment is being driven by ongoing improvements in breast reconstruction techniques that improve implant positioning accuracy and shorten recovery times and discomfort. In the coming years, the adoption of ADMs (acellular dermal matrix) is projected to outpace that of breast implants due to the incorporation of cutting-edge technology, such as the conversion from a two-step to a single-step breast reconstruction method.
The rising incidence of breast cancer worldwide and the rise in the number of breast reconstruction treatments are anticipated to boost the global market for breast reconstruction surgery and treatment.
The global market is predicted to expand 1.8X its current size by the end of 2033.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 4.41% |
| Jul-Dec (H2), 2021 (A) | 5.57% |
| Jan-Jun (H1),2022 Projected (P) | 4.35% |
| Jan-Jun (H1),2022 Outlook (O) | 4.59% |
| Jul-Dec (H2), 2022 Outlook (O) | 6.03% |
| Jul-Dec (H2), 2022 Projected (P) | 5.43% |
| Jan-Jun (H1), 2023 Projected (P) | 4.91% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 23↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 17↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 60↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 46↑ |
Principal Consultant
After a mastectomy, some women choose to have breast reconstruction surgery. Others avoid it because they don't know about it or because they have other health issues, like obesity, skin-thinness, or alterations in blood flow dynamics.
These women have access to breast reconstruction alternatives like custom breast prostheses and going flat. Additionally, for patients who have had a single mastectomy, a personalized breast prosthesis can give symmetry with the intact breast and match the woman's exact contour.
This prosthesis costs from $100 and $500 for high-quality goods, which is significantly less than breast reconstruction. However, the market for breast reconstruction surgery and treatments is significantly constrained by alternatives, notably non-surgical methods.
The market for breast reconstruction surgery and treatments may see significant increase because of the introduction of 3D-printed implants. German companies BellaSeno and Evonik have joined to develop 3D breast implant technology.
Senella breast scaffolds from BellaSeno will be composed of Resomer bioresorbable polymer from Evonik, replacing silicone implants, which have raised significant safety concerns.
The first human clinical studies utilising the Senella scaffolds were going to start in Germany in 2019, according to BellaSeno and Resomer plans. Evonik has also made their Resomer polymer available for use in commercial and clinical applications.
The scaffolds, which are constructed from liposuctioned human fat, are designed to direct the development of healthy tissue. This product is meant to be used after surgery for augmentation, reconstruction, or revision. This is gradually absorbed by the body and replaced with native breast tissue.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 32.0% |
| Market Share (2033) | 32.1% |
| BPS Analysis | 9 |
| Country | Brazil |
|---|---|
| Market Share (2023) | 15.0% |
| Market Share (2033) | 15.5% |
| BPS Analysis | 42 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.9% |
| Market Share (2033) | 6.0% |
| BPS Analysis | 2 |
| Country | Mexico |
|---|---|
| Market Share (2023) | 5.5% |
| Market Share (2033) | 5.4% |
| BPS Analysis | -9 |
| Country | South Korea |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 5.5% |
| BPS Analysis | 35 |
The United States is set to hold a share of around 32.0% of the global market in 2023.
The market is expanding in the United States as a result of high incidence of breast cancer, rising breast augmentation operations, and developed healthcare infrastructure.
For instance, breast augmentation was one of the top five cosmetic surgery treatments in the United States in 2020, according to the American Society of Plastic Surgeons' 2020 report. It is projected that the region's breast implant market will rise due to the rising incidence of breast cancer. For instance, GLOBOCAN 2020 study reveals that there have been 253,465 new cases of breast cancer in the USA region.
Germany is set to hold a share of 5.9% of the global market in 2023.
The rising prevalence of breast cancer is the primary factor influencing the regional market. For instance, according to World Health Organization, in 2020 around total 69,697 new cases of breast cancer were found in Germany. Due to the rising incidence of breast cancer worldwide, there is a strong need for breast reconstruction surgeries. Because of rising hereditary diseases in women, rising healthcare costs, and changes in government policy, breast reconstruction surgery and treatment is becoming more common.
China is set to expand at a CAGR of 3.3% over the forecast period.
The rise in awareness of breast reconstruction surgery and the fast rising breast cancer population are both responsible for the growth. For instance, the NCBI data revealed that there were about 303,600 new instances of breast cancer and 70,400 fatalities from the disease in China.
Furthermore, according to a similar source, the incidence rate and death rate in China are predicted to rise by 2030 due to changing demographics and hazards. More than 76.5% of women preferred breast reconstruction following mastectomy, according to a research by a similar source. As a result, the market is anticipated to increase significantly during the next years.
Tissue expanders are expected to hold a market share of 64.5% in 2023. After mastectomy tissue expanders are utilized to increase the amount of tissue. These products are placed during mastectomy or in after the patient have cured and finished cancer treatment in second surgery.
Tissue expanders are safe and effective product choose by patients. It is a desirable option since there is no donor defect, the recovery period is shorter, there is less chance of morbidity, and women can choose the size of the reconstructed breast. These benefits of it is anticipated for segment growth.
As per procedures, the market has been segmented into immediate, delayed, and revision. The immediate procedure segment is set to hold 30.1% revenue share in 2023.
In order to reduce the need for subsequent procedures and the risks involved with so surgeries, there is evidence that suggests rapid breast reconstruction is better to delayed breast reconstruction. It has been demonstrated that immediate breast reconstruction reduces recovery time, costs, and improves quality of life and psychological wellbeing.
After a mastectomy, people who still have the appropriate amounts of skin and nipple make suitable candidates for rapid breast reconstruction with a conventional implant. Rapid reconstruction after a mastectomy with skin preservation yields the best cosmetic results. These affirmatory factors are expected to propel the segment growth.
Bilateral is expected to hold a market share of 62.23% in 2023. Women who choose to have bilateral preventative mastectomy or those who have unilateral breast cancer and a high risk of acquiring a contralateral malignancy may all benefit from bilateral breast reconstruction. Women may think about bilateral breast reconstruction in this situation in an effort to enhance their external attractiveness and ultimately enhance their internal sense of attractiveness and femininity.
One benefit of bilateral breast reconstruction is that the patient's reconstructed breast does not have to match the contralateral, native breast; rather, the patient's reconstructed breast can be different from the contralateral, native breast. This benefit of it is expected to lead the segment.
Hospitals are expected to hold a market share of 60.9% in 2023. A growth of hospitals around the world is to blame for the segment's domination. For instance, hospitals account for 80% of the Indian healthcare market, according to the Athar Institute of Health Management & Studies. According to The Canadian Encyclopedia, there are also 193 private hospitals and 706 public hospitals in Canada.
Medical tourism has increased globally as well. As medical tourism grows, it is projected that hospitals' medical facility standards would improve. The abovementioned variables are expected to have a substantial impact on the hospitals segment's growth during the projection period.
The breast reconstruction surgery and treatment market is competitive and has several established companies. To increase their market share, numerous players use tactics like geographic growth, mergers and acquisitions, collaborations, and the launch of new products. Players in both the global and local markets profit from a sizable distributor marketing network.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the breast reconstruction surgery and treatment space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Procedure, Surgery, End-User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at US$ 901.3 million in 2023.
The growth potential of the market is 5.9% through 2033.
Introduction of 3D-printed implants is expected to create opportunities for players.
Availability of alternative methods like non-surgical procedures is likely to limit market growth.
Surging demand for acellular dermal matrix is likely to provide growth prospects for the market players.
1. Executive Summary | Breast Reconstruction Surgery and Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Recent Product Approvals/ Launches
4.3. Breast Reconstruction Surgery Volume
4.4. Key Promotional Strategies, By Manufacturers
4.5. Supply Chain Analysis
4.6. Porter’s Five Forces Analysis
4.7. Regulatory Dynamics
4.8. PESTEL Analysis
5. Market Background
5.1. Macro - Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Overview
5.1.3. Global Cosmetic Surgery Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Breast Cancer Prevalence
5.2.2. Increasing Number of Breast Reconstruction Procedures
5.2.3. Surge in Demand for Acellular Dermal Matrix
5.2.4. Increased Awareness for Breast Reconstruction Surgery and Treatment
5.2.5. Availability of Reimbursements
5.2.6. Growing Practice for Breast Reconstruction
5.2.7. Technological Advancements
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue by Product
6.1.2. Revenue by Procedure
6.1.3. Revenue by Surgery
6.1.4. Revenue by End User
6.1.5. Revenue by Country
6.2. 2022 Market Scenario
7. Global Market Demand (Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y – o – Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (In Value or Size in US$ Million) Trend by Product, 2017 to 2022
8.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Product, 2023 to 2033
8.3.1. Breast Implant
8.3.1.1. Silicone Implants
8.3.1.2. Saline Implants
8.3.2. Tissue Expanders
8.3.3. Acellular Dermal Matrix
8.4. Market Attractiveness Analysis by Product
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Procedure
9.1. Introduction / Key Findings
9.2. Historical Market Size (In Value or Size in US$ Million) Trend by Procedure, 2017 to 2022
9.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Procedure, 2023 to 2033
9.3.1. Immediate
9.3.2. Delayed
9.3.3. Revision
9.4. Market Attractiveness Analysis by Procedure
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Surgery
10.1. Introduction / Key Findings
10.2. Historical Market Size (In Value or Size in US$ Million) Trend by Surgery, 2017 to 2022
10.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Surgery, 2023 to 2033
10.3.1. Unilateral
10.3.2. Bilateral
10.4. Market Attractiveness Analysis by Surgery
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (In Value or Size in US$ Million) Trend by End User, 2017 to 2022
11.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Cosmetology Clinics and Ambulatory surgical centres
11.4. Market Attractiveness Analysis by End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (In Value or Size in US$ Million) Analysis by Region, 2017 to 2022
12.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. The USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Procedure
13.3.4. By Surgery
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Procedure
13.4.4. By Surgery
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Procedure
13.8.1.2.3. By Surgery
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Procedure
13.8.2.2.3. By Surgery
13.8.2.2.4. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Procedure
14.3.4. By Surgery
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Procedure
14.4.4. By Surgery
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Procedure
14.8.1.2.3. By Surgery
14.8.1.2.4. By End User
14.8.2. Mexico Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Procedure
14.8.2.2.3. By Surgery
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Procedure
14.8.3.2.3. By Surgery
14.8.3.2.4. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. United Kingdom
15.3.1.3. France
15.3.1.4. Italy
15.3.1.5. Russia
15.3.1.6. Spain
15.3.1.7. BENELUX
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Procedure
15.3.4. By Surgery
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Procedure
15.4.4. By Surgery
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Procedure
15.8.1.2.3. By Surgery
15.8.1.2.4. By End User
15.8.2. United Kingdom Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Procedure
15.8.2.2.3. By Surgery
15.8.2.2.4. By End User
15.8.3. Russia Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Procedure
15.8.3.2.3. By Surgery
15.8.3.2.4. By End User
15.8.4. Spain Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Procedure
15.8.4.2.3. By Surgery
15.8.4.2.4. By End User
15.8.5. France Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Procedure
15.8.5.2.3. By Surgery
15.8.5.2.4. By End User
15.8.6. Italy Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Product
15.8.6.2.2. By Procedure
15.8.6.2.3. By Surgery
15.8.6.2.4. By End User
15.8.7. BENELUX Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Product
15.8.7.2.2. By Procedure
15.8.7.2.3. By Surgery
15.8.7.2.4. By End User
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Product
16.3.3. By Procedure
16.3.4. By Surgery
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Procedure
16.4.4. By Surgery
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Procedure
16.8.1.2.3. By Surgery
16.8.1.2.4. By End User
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Procedure
16.8.2.2.3. By Surgery
16.8.2.2.4. By End User
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Procedure
16.8.3.2.3. By Surgery
16.8.3.2.4. By End User
16.8.4. Thailand Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Procedure
16.8.4.2.3. By Surgery
16.8.4.2.4. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Procedure
17.3.4. By Surgery
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Procedure
17.4.4. By Surgery
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Procedure
17.8.1.2.3. By Surgery
17.8.1.2.4. By End User
17.8.2. Japan Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Procedure
17.8.2.2.3. By Surgery
17.8.2.2.4. By End User
17.8.3. South Korea Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Procedure
17.8.3.2.3. By Surgery
17.8.3.2.4. By End User
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Procedure
18.3.4. By Surgery
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Procedure
18.4.4. By Surgery
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Procedure
18.8.1.2.3. By Surgery
18.8.1.2.4. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Procedure
18.8.2.2.3. By Surgery
18.8.2.2.4. By End User
19. Middle East & Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (In Value or Size in US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (In Value or Size in US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Procedure
19.3.4. By Surgery
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Procedure
19.4.4. By Surgery
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Procedure
19.8.1.2.3. By Surgery
19.8.1.2.4. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Procedure
19.8.2.2.3. By Surgery
19.8.2.2.4. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Procedure
19.8.3.2.3. By Surgery
19.8.3.2.4. By End User
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Procedure
19.8.4.2.3. By Surgery
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. Mentor Worldwide LLC (Johnson & Johnson)
21.2.1.1. Overview
21.2.1.2. Product Portfolio
21.2.1.3. Key Financials
21.2.1.4. Sales Footprint
21.2.1.5. SWOT Analysis
21.2.1.6. Strategy Overview
21.2.1.6.1. Marketing Strategy
21.2.1.6.2. Product Strategy
21.2.1.6.3. Channel Strategy
21.2.2. Allergan Aesthetics (An AbbVie Company)
21.2.2.1. Overview
21.2.2.2. Product Portfolio
21.2.2.3. Key Financials
21.2.2.4. Sales Footprint
21.2.2.5. SWOT Analysis
21.2.2.6. Strategy Overview
21.2.2.6.1. Marketing Strategy
21.2.2.6.2. Product Strategy
21.2.2.6.3. Channel Strategy
21.2.3. Sientra
21.2.3.1. Overview
21.2.3.2. Product Portfolio
21.2.3.3. Key Financials
21.2.3.4. Sales Footprint
21.2.3.5. SWOT Analysis
21.2.3.6. Strategy Overview
21.2.3.6.1. Marketing Strategy
21.2.3.6.2. Product Strategy
21.2.3.6.3. Channel Strategy
21.2.4. POLYTECH Health & Aesthetics GmbH
21.2.4.1. Overview
21.2.4.2. Product Portfolio
21.2.4.3. Key Financials
21.2.4.4. Sales Footprint
21.2.4.5. SWOT Analysis
21.2.4.6. Strategy Overview
21.2.4.6.1. Marketing Strategy
21.2.4.6.2. Product Strategy
21.2.4.6.3. Channel Strategy
21.2.5. GC Aesthetics
21.2.5.1. Overview
21.2.5.2. Product Portfolio
21.2.5.3. Key Financials
21.2.5.4. Sales Footprint
21.2.5.5. SWOT Analysis
21.2.5.6. Strategy Overview
21.2.5.6.1. Marketing Strategy
21.2.5.6.2. Product Strategy
21.2.5.6.3. Channel Strategy
21.2.6. Sebbim
21.2.6.1. Overview
21.2.6.2. Product Portfolio
21.2.6.3. Key Financials
21.2.6.4. Sales Footprint
21.2.6.5. SWOT Analysis
21.2.6.6. Strategy Overview
21.2.6.6.1. Marketing Strategy
21.2.6.6.2. Product Strategy
21.2.6.6.3. Channel Strategy
21.2.7. Establishment Labs S.A.
21.2.7.1. Overview
21.2.7.2. Product Portfolio
21.2.7.3. Key Financials
21.2.7.4. Sales Footprint
21.2.7.5. SWOT Analysis
21.2.7.6. Strategy Overview
21.2.7.6.1. Marketing Strategy
21.2.7.6.2. Product Strategy
21.2.7.6.3. Channel Strategy
21.2.8. Integra Lifesciences
21.2.8.1. Overview
21.2.8.2. Product Portfolio
21.2.8.3. Key Financials
21.2.8.4. Sales Footprint
21.2.8.5. SWOT Analysis
21.2.8.6. Strategy Overview
21.2.8.6.1. Marketing Strategy
21.2.8.6.2. Product Strategy
21.2.8.6.3. Channel Strategy
21.2.9. RTI Surgical Holdings
21.2.9.1. Overview
21.2.9.2. Product Portfolio
21.2.9.3. Key Financials
21.2.9.4. Sales Footprint
21.2.9.5. SWOT Analysis
21.2.9.6. Strategy Overview
21.2.9.6.1. Marketing Strategy
21.2.9.6.2. Product Strategy
21.2.9.6.3. Channel Strategy
21.2.10. Idel Implant Incorporated
21.2.10.1. Overview
21.2.10.2. Product Portfolio
21.2.10.3. Key Financials
21.2.10.4. Sales Footprint
21.2.10.5. SWOT Analysis
21.2.10.6. Strategy Overview
21.2.10.6.1. Marketing Strategy
21.2.10.6.2. Product Strategy
21.2.10.6.3. Channel Strategy
21.2.11. Laboratoires Arion
21.2.11.1. Overview
21.2.11.2. Product Portfolio
21.2.11.3. Key Financials
21.2.11.4. Sales Footprint
21.2.11.5. SWOT Analysis
21.2.11.6. Strategy Overview
21.2.11.6.1. Marketing Strategy
21.2.11.6.2. Product Strategy
21.2.11.6.3. Channel Strategy
21.2.12. Silimed
21.2.12.1. Overview
21.2.12.2. Product Portfolio
21.2.12.3. Key Financials
21.2.12.4. Sales Footprint
21.2.12.5. SWOT Analysis
21.2.12.6. Strategy Overview
21.2.12.6.1. Marketing Strategy
21.2.12.6.2. Product Strategy
21.2.12.6.3. Channel Strategy
21.2.13. Guangzhou Wanhe Plastic Material Co., Ltd.
21.2.13.1. Overview
21.2.13.2. Product Portfolio
21.2.13.3. Key Financials
21.2.13.4. Sales Footprint
21.2.13.5. SWOT Analysis
21.2.13.6. Strategy Overview
21.2.13.6.1. Marketing Strategy
21.2.13.6.2. Product Strategy
21.2.13.6.3. Channel Strategy
21.2.14. Cereplas
21.2.14.1. Overview
21.2.14.2. Product Portfolio
21.2.14.3. Key Financials
21.2.14.4. Sales Footprint
21.2.14.5. SWOT Analysis
21.2.14.6. Strategy Overview
21.2.14.6.1. Marketing Strategy
21.2.14.6.2. Product Strategy
21.2.14.6.3. Channel Strategy
21.2.15. Hansbiomed
21.2.15.1. Overview
21.2.15.2. Product Portfolio
21.2.15.3. Key Financials
21.2.15.4. Sales Footprint
21.2.15.5. SWOT Analysis
21.2.15.6. Strategy Overview
21.2.15.6.1. Marketing Strategy
21.2.15.6.2. Product Strategy
21.2.15.6.3. Channel Strategy
21.2.16. PMT Corporation
21.2.16.1. Overview
21.2.16.2. Product Portfolio
21.2.16.3. Key Financials
21.2.16.4. Sales Footprint
21.2.16.5. SWOT Analysis
21.2.16.6. Strategy Overview
21.2.16.6.1. Marketing Strategy
21.2.16.6.2. Product Strategy
21.2.16.6.3. Channel Strategy
21.2.17. PFM Medical
21.2.17.1. Overview
21.2.17.2. Product Portfolio
21.2.17.3. Key Financials
21.2.17.4. Sales Footprint
21.2.17.5. SWOT Analysis
21.2.17.6. Strategy Overview
21.2.17.6.1. Marketing Strategy
21.2.17.6.2. Product Strategy
21.2.17.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Breast Reconstruction Surgery and Treatment Market
